ReviewNature reviews. Drug discovery2026
Towards mRNA therapeutics 2.0.
Review in Nature reviews. Drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- circRNA-programmed macrophages enable localized antibody therapy.Molecular therapy. Nucleic acids · 2026Article
- RNA-Based Therapeutics in Genetic Neurodevelopmental Disorders: Bridging Molecular Genetics and Precision Medicine.International journal of molecular sciences · 2026Review
- Two Classes of Protein Therapeutics: Why Dose-Response Architecture Defines the Boundary of mRNA Medicines.Pharmaceutics · 2026Review
- Target, silence, replace: a review on RNA-based drugs in modern medicine.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
mRNA technology, which has enabled the rapid development of vaccines for infectious diseases, also holds great promise for a new generation of therapies for a host of rare and common diseases. A decade of clinical trials are beginning to clarify the key barriers to unlock the transformative potential of mRNA drugs, which are being addressed with novel interdisciplinary technical advances that, in some cases, are integrating the fields of gene, cell and mRNA therapies. Here, we review the scientific insights from a select group of clinical studies on mRNA-based drugs, including enzyme replacement therapies for rare diseases, cancer immunotherapies, genome-modifying therapies, and immune cell reprogramming therapies for cancer and autoimmune diseases. Several innovative approaches such as clinically tractable in vivo delivery systems, the development of completely 'immune-silent' mRNA-vehicle formulations that allow repeated administration and the development of approaches for preferential delivery to organs other than the liver would expedite the development of mRNA therapeutics 2.0.
Indexed as
Identifiers
42236989What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.